Navigation Links
Investigational immune intervention slows brain shrinkage in Alzheimer's patients
Date:4/13/2010

More details about the study's cognitive testing results will be reported in a later presentation at the AAN meeting by Dr. Diamanto Tsakanikas, who performed cognitive and other testing of the study's participants. Dr. Tsakanikas is a clinical assistant attending neuropsychologist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and an instructor of neuropsychology in the Department of Neurology and Neuroscience at Weill Cornell Medical College. While conducting the testing, Dr. Tsakanikas was blinded to whether patients were receiving IGIV or placebo and to the IGIV dose.

When the unblinded study results were later analyzed, her testing indicated that AD patients who received uninterrupted IGIV for 18 months showed significantly less decline in their overall function and thinking abilities than AD patients initially given an inactive placebo. In some cases, IGIV intervention resulted in improvements in certain areas of cognitive functioning. "Functions mediated by the frontal regions of the brain showed the most consistent benefits in IGIV responders," says Dr. Tsakanikas.

The Phase II study involved 24 patients with mild to moderate Alzheimer's disease who were randomly assigned to receive IGIV (16 patients) or saline placebo (eight patients) for six months. Over the following 12 months, the initially placebo-treated group were subsequently received various doses of IGIV while the other 16 patients had uninterrupted IGIV at the initially assigned dose. The study included a comparison of four dosing regimens of IGIV, with doses ranging from 0.2 g/kg every two weeks to 0.8 g/kg every four weeks. "The Phase II study was carried out with the explicit goal of determining whether further testing of IGIV for Alzheimer's was justified," Dr. Relkin points out. "It succeeded in achieving that goal with a relatively small number of subjects. However, we now have to await the results of the larger, pivotal Phase III study to establish the mag
'/>"/>

Contact: John Rodgers
jdr2001@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. The immune systems guard against cancer
2. Study details machinery of immune protection against inflammatory diseases like colitis
3. Penn researchers identify immune cells that fight parasites may promote allergies and asthma
4. Vitamin D crucial to activating immune defenses
5. HIV vaccine strategy expands immune responses
6. An apple a day? Study shows soluble fiber boosts immune system
7. Pesky aphid thrives despite weak immune system
8. Research could lead to way to halt deadly immune response
9. Rejuvenating the old immune system
10. Early immune response needed for hit-and-hide cancer viruses
11. Enzyme necessary for development of healthy immune system
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... 24, 2015 Research and Markets ( ... "Global Iris Recognition Market 2015-2019" report to their ... Recognition market to grow at a CAGR of 23.5 ... covers the present scenario and the growth prospects of ... To calculate the market size, the report considers the ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Dr Veerle Huvenne of the United Kingdom,s National Oceanography Centre ... million Euros over five years to map complex habitats in ... The European Research Council (ERC) ,Starting Grant, scheme aims to ... own research groups. The grants are highly competitive, and this ...
... October 27, 2010 TEL AVIV, Israel Assembled ... Israel under the EUREKA Chairmanship year, EUREKA,s High Level ... of promising cooperative R&D projects in a variety of ... accordance with EUREKA,s strategic targets defined for the 2010-2011 ...
... Human Reproduction and Embryology (ESHRE) has published the first textbook ... English language. A Dutch textbook, in layout and ... higher professional education (Master,s level), was the basis for this ... nurses working in reproductive health. For a net ...
Cached Biology News:European R&D leaders assembled in Tel Aviv will invest $70 million in joint R&D initiatives 2
(Date:4/17/2015)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a ... commercializes proprietary technologies and products for advanced microarray ... approval from the TSX Venture Exchange to extend ... warrants ("the Warrants") of the Company, which were ... private placement financing. Each Warrant entitles ...
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery company, ... Memorandum of Understanding with the Feinstein Institute for ... York to collaborate with the objective ... The collaboration brings together the drug discovery ... expertise of the Feinstein Institute in neurosciences and ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 LC ... proteomics technologies, announced today that it is seeking ... an innovative multiplex PCR based targeted sequencing technology. ... sequence analysis, that enables accurate detection of rare ... and Omega-Primerâ„¢ technologies. The company will collaborate with ...
(Date:4/16/2015)... Carolina (PRWEB) April 17, 2015 ... steam system services, released their newly designed, state-of-the-art ... The customer facing website effectively promotes the Spirax ... , All the information that a site visitor ... system services, company capabilities, industries serviced, the latest ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Spirax Sarco website has a new look 2
... Entrepreneurial Excellence in Emerging Category, LOS ANGELES, ... announced that Dr. Donald Rice, Founder, President, & ... Year(R) 2008 Award in the,Emerging category in the ... LLP, the award recognizes outstanding entrepreneurs who are ...
... Pathway Would Also Lower Total,Expenditures for Biologics by $25 ... The Congressional Budget,Office (CBO) today released a cost analysis ... biologics -- or biogenerics -- would save,the federal government ... biologics by $25 billion over the same time period., ...
... advanced formula,scar gel is a unique patented silicone ... standard for scar treatment and abnormal scar,prevention. The ... is ONLY available from Advanced Bio-Technologies, Inc.(ABT)., ... label. Doctors,and customers should not be misled by ...
Cached Biology Technology:Agensys Founder, President, & CEO Dr. Donald Rice Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Winner for the Greater Los Angeles Area 2Agensys Founder, President, & CEO Dr. Donald Rice Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Winner for the Greater Los Angeles Area 3CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years 2
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Mouse monoclonal [CAT-1] to Chloramphenicol Acetyltransferase ( Abpromise for all tested applications)....
... Cells are designed for use with the ... strain MaV203 contains deletions in the endogenous ... GAL4-based two-hybrid systems. The strain also has ... ProQuest bait and prey vectors. MaV203 contains ...
Biology Products: